🐾FDA Seeks Input on Cannabis-Derived Products in Veterinary Use
Use of Cannabis-Derived Products, Including Cannabidiol, in Veterinary Practice; Request for Information
Summary
The Food and Drug Administration (FDA, the Agency, or we) is soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDPs) in animals, with an emphasis on cannabidiol (CBD) products and general trends associated with those products, including information about: usage trends (e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns. This information will enhance the Center for Veterinary Medicine's (CVM's) knowledge of potential safety signals associated with these products, in addition to aiding our understanding of veterinarians' experiences related to the use of CDPs for their animal patients.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The FDA's request for information on cannabis-derived products in veterinary practice presents significant implications for businesses involved in the production, distribution, or veterinary use of these products, especially regarding compliance with upcoming regulations and standards that could affect market practices and safety protocols.